SOPHiA GENETICS (SOPH) CEO sells 8,500 shares under 10b5-1 plan
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
SOPHiA GENETICS SA Chief Executive Officer Jurgi Camblong sold 8,500 Ordinary Shares in an open-market transaction at a weighted average price of $5.2354 per share. Following the sale, he directly holds 3,620,995 shares.
The sale was made pursuant to a duly adopted trading plan under Rule 10b5-1(c). The shares were sold in multiple trades at prices ranging from $5.13 to $5.42.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 8,500 shares ($44,501)
Net Sell
1 txn
Insider
Camblong Jurgi
Role
Chief Executive Officer
Sold
8,500 shs ($45K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Ordinary Shares | 8,500 | $5.2354 | $45K |
Holdings After Transaction:
Ordinary Shares — 3,620,995 shares (Direct, null)
Footnotes (1)
- Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.13 to $5.42, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Key Figures
Shares sold: 8,500 shares
Weighted average sale price: $5.2354 per share
Post-transaction holdings: 3,620,995 shares
+2 more
5 metrics
Shares sold
8,500 shares
Open-market sale of Ordinary Shares
Weighted average sale price
$5.2354 per share
Average price for the 8,500 shares sold
Post-transaction holdings
3,620,995 shares
Shares directly held after the sale
Price range of trades
$5.13–$5.42 per share
Range of individual transaction prices
Net shares sold
8,500 shares
Net sell direction from transactionSummary
Key Terms
Rule 10b5-1(c), weighted average price, open-market sale, Ordinary Shares
4 terms
Rule 10b5-1(c) regulatory
"Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c)."
Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
FAQ
What insider transaction did SOPHiA GENETICS (SOPH) report for Jurgi Camblong?
SOPHiA GENETICS reported that CEO Jurgi Camblong sold 8,500 Ordinary Shares. The transaction was an open-market sale executed under a Rule 10b5-1(c) trading plan, indicating it was pre-arranged rather than a spontaneous market decision.
Was the SOPHiA GENETICS (SOPH) CEO sale made under a Rule 10b5-1 plan?
Yes, the transaction was made pursuant to a duly adopted trading plan under Rule 10b5-1(c). Such plans pre-schedule trades, helping separate routine portfolio management from timing based on short-term information.
What type of security did the SOPHiA GENETICS (SOPH) insider sell?
The reported transaction involved Ordinary Shares of SOPHiA GENETICS SA. It was classified as a non-derivative open-market sale, meaning the insider sold actual shares rather than exercising or converting derivative securities such as options or warrants.